<DOC>
	<DOCNO>NCT02406690</DOCNO>
	<brief_summary>The purpose study determine difference exist RNA molecule , biochemical process methylation , estrogen receptor bind patient fail produce adequate endometrium synthetic embryo transfer cycle compare patient whose endometrium thickness within normal limit .</brief_summary>
	<brief_title>Endometrial Receptivity Profile Patients With Endometrial Proliferation Defects</brief_title>
	<detailed_description>The purpose study determine difference may exist RNA molecule , biochemical process methylation , estrogen receptor binding ( group proteins cell activate hormone estrogen ) patient fail produce adequate endometrium ( uterine lining ) synthetic embryo transfer cycle compare patient whose endometrium thickness within normal limit . Appropriate embryo development luteal phase ( fertilization implantation occur ) transformation endometrium create small window opportunity successful implantation occur . The interaction embryo endometrium complex poorly understood . The endometrium , consist two layer call functionalis basalis , go change menstrual cycle . The change occur need successful implantation embryo . The proliferative phase menstrual cycle primarily govern estrogen responsible thicken endometrium . Progesterone primarily control last half menstrual cycle cause change allow embryo implantation . Through vitro fertilization ( IVF ) , investigator see correct thickness endometrium marker successful implantation ongoing pregnancy , although reason entirely clear . In order well understand process may occur endometrium , investigator conduct study evaluate biochemical marker patient show failure proliferate previous synthetic IVF frozen cycle biochemical marker control patient know endometrial pathology .</detailed_description>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Inclusion Criteria Case Group : Diagnosis endometrial insufficiency prior cycle maximal endometrial thickness ≤ 6mm , abnormal endometrial pattern ( failure attain trilaminar appearance ) , persistent endometrial fluid . Exclusion Criteria Case Control Groups : Any evidence surgically induced endometrial insufficiency ( Asherman 's syndrome ) Presence hydrosalpinges communicate endometrial cavity Any contraindication undergo estrogen stimulation endometrium Age ≥35 year smoke ≥15 cigarette per day Multiple risk factor arterial cardiovascular disease ( smoking , diabetes , hypertension ) Hypertension ( systolic ≥140 mmHg diastolic ≥90 mmHg ) Venous thromboembolism ( current history ) Known thrombogenic mutation Known ischemic heart disease History stroke Complicated valvular heart disease ( pulmonary hypertension , risk atrial fibrillation , history subacute bacterial endocarditis ) Systemic lupus erythematosus ( positive unknown antiphospholipid antibody ) Migraine aura age Breast cancer Cirrhosis Hepatocellular adenoma malignant hepatoma History undiagnosed abnormal uterine bleeding . Allergic reaction estradiol valerate , progesterone oil , leuprolide acetate Known pregnancy delivery within past 6 month Breastfeeding Obesity &gt; 35 kg/m2</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Endometrial Insufficiency</keyword>
	<keyword>Endometrial Receptivity</keyword>
</DOC>